5 June 2026

HbA1c and Weight Outcomes for Individuals With T2D Persistent on Oral Semaglutide 25 mg: A PIONEER PLUS Post Hoc Analysis

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress poster

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)